SCHEMBL6388251

SCHEMBL6388251

Cc1ccc(N(CCC(C)C)C(=O)C2CCCCC2)c(S)c1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 2/20 0.43
▸ CNR1 P21554 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.42
▸ IDO1 P14902 2/20 0.38
▸ MAPT P10636 1/20 0.37
▸ GAA P10253 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ NR1H4 Q96RI1 2/20 0.36
▸ ITGB1 P05556 1/20 0.35
▸ ITGA4 P13612 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ ACHE P22303 1/20 0.34
▸ CCR5 P51681 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6393147 0.91 TDP1 (0.42) CNR2CNR1TDP1IDO1MAPT
SCHEMBL6386892 0.83 TDP1 (0.43) CNR2CNR1TDP1NR1H4ITGB1
SCHEMBL6388805 0.82 TDP1 (0.44) CNR2CNR1TDP1NR1H4ITGB1
SCHEMBL529153 0.81 TDP1 (0.40) CNR2CNR1TDP1MAPTGAA
SCHEMBL18039231 0.78 TDP1 (0.40) CNR2CNR1TDP1IDO1MAPT
SCHEMBL6386762 0.75 LMNA (0.41) CNR2CNR1TDP1MAPTITGB1
SCHEMBL7250262 0.74 TDP1 (0.48) TDP1LMNASMN1; SMN2ALDH1A1ACHE
SCHEMBL527982 0.73 TDP1 (0.42) CNR2CNR1TDP1NR1H4ITGB1
SCHEMBL528739 0.73 LMNA (0.44) CNR2CNR1LMNASMN1; SMN2ACHE
SCHEMBL6388980 0.72 TDP1 (0.46) TDP1LMNASMN1; SMN2ALDH1A1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1603553-A2 PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS JAPAN TOBACCO INC. (JP) 2005-12-14 — — EP disclosed
WO-2004082593-A2 PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS JAPAN TOBACCO INC. (JP) 2004-09-30 — — WO disclosed
Send feedback